Get the Stockscreener App
451.24
0.61%
-2.765
Pre-market:
451.00
-0.235
-0.05%
Vertex Pharmaceuticals Inc stock is traded at $451.24, with a volume of 1.15M.
It is down -0.61% in the last 24 hours and down -6.19% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$454.00
Open:
$458.42
24h Volume:
1.15M
Relative Volume:
0.79
Market Cap:
$114.63B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
29.43
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
-3.19%
1M Performance:
-6.19%
6M Performance:
+18.83%
1Y Performance:
-10.33%
1-Day Range:
$450.97
$463.78
1-Week Range:
$449.75
$468.45
52-Week Range:
$362.50
$513.98
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? - The Motley Fool
Westview Management dba Westview Investment Advisors Invests $2.85 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gradient Investments LLC Has $19.76 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Nordea Investment Management AB Has $202.61 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Tokenized Stock (Ondo) price today, VRTXon to USD live price, marketcap and chart - CoinMarketCap
How Vertex’s IgA Nephropathy Data and Accelerated FDA Pathway At Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story - Yahoo Finance
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
Cooper Financial Group Acquires 3,021 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock faces pressure amid CF dominance and pipeline uncertainties in 2026 - AD HOC NEWS
Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX - Benzinga
Form 144 VERTEX PHARMACEUTICALS INC / MA For: 4 March - Investing.com
Oppenheimer upgrades Vertex Pharmaceuticals (VRTX) - MSN
Promising Biotech Stocks To Follow TodayMarch 20th - MarketBeat
Vertex Pharma stock faces pressure amid CF growth and pipeline uncertainties - AD HOC NEWS
Is CRISPR Therapeutics Stock a Buy Now? - AOL.com
Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag? - TradingView
CIBC Bancorp USA Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals (VRTX) Offering Value After Recent Share Price Pullback? - simplywall.st
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Positive RAINIER Trial Update And Accelerated IgAN Filing - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
RBC Capital reiterates Vertex stock rating on competitive concerns - Investing.com
Swiss Life Asset Management Ltd Buys 6,045 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Groupama Asset Management Trims Stake in Vertex Pharmaceuticals - National Today
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $550 From $515, Maintains Overweight Rating - marketscreener.com
Argus Adjusts PT on Vertex Pharmaceuticals to $520 From $475, Maintains Buy Rating - marketscreener.com
Mirabella Financial Services LLP Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Argus raises Vertex stock price target to $520 on CF franchise - Investing.com
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Groupama Asset Managment Sells 17,916 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Stock In Shambles: Down 9.5% With 6-Day Losing Streak - Trefis
Vertex Pharmaceuticals Stock 6-Day Losing Spree: Stock Falls -9.5% - Trefis
Danske Bank A S Makes New $64.42 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by AIA Group Ltd - MarketBeat
Vertex Pharmaceuticals (VRTX) Upgraded to Buy by Maxim Group | V - GuruFocus
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals (VRTX) Gains Amid Optimistic Outlook and Upgrade - GuruFocus
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Buy" at Maxim Group - MarketBeat
Vertex Pharmaceuticals Stock Slides 7.3% With A 5-Day Losing Spree - Trefis
Vertex Pharmaceuticals Stock Plummets -7.3% With 5-Day Losing Streak - Trefis
Vertex Pharmaceuticals Incorporated $VRTX is Provident Investment Management Inc.'s 4th Largest Position - MarketBeat
Fierce Biotech Layoff Tracker 2026: Gossamer lays off 48%; Bicycle deflates - Fierce Biotech
Physician Views Preview: How clinically meaningful are Vertex's Phase III data for povetacicept? - FirstWord Pharma
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 2,329 Shares - MarketBeat
Vertex Pharmaceuticals EVP and CMO Carmen Bozic Sells Shares - TradingView
Vertex (VRTX) EVP and CMO Carmen Bozic sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan
Top Biotech Stocks To Follow TodayMarch 17th - MarketBeat
Mirabella Financial Services LLP Has $2.10 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Focus Partners Wealth Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):